Analysis of the efficacy and cure possibility of osimertinib in the treatment of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the main type of lung cancer, and its treatment has always been the focus of medical research. In recent years, with the rise of molecular targeted therapy, EGFR mutant inhibitors have become more and more widely used in the treatment of non-small cell lung cancer. Osimertinib (Osimertinib), as a third-generation EGFRtyrosine kinase inhibitor, has attracted much attention for its efficacy and cure potential in the treatment of NSCLC.

Osimertinib has demonstrated significant clinical efficacy in the treatment of EGFR non-small cell lung cancer patients with sensitive mutations. Multiple clinical trial data show that osimertinib, as a first-line treatment drug, can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients. Compared with first- and second-generation EGFR-TKIs, osimertinib has a higher blood-brain barrier penetration ability and therefore also shows better results in the treatment of patients with brain metastases.

In actual clinical applications, the efficacy of osimertinib is usually evaluated through the improvement of patients' clinical symptoms and imaging examinations. After receiving osimertinib treatment, many patients will have significant relief from symptoms such as cough, chest tightness, and chest pain, and their quality of life will be significantly improved. At the same time, imaging examinations such as lung CT will also show signs of improvement such as shrinkage of lung masses and reduction of pleural effusion.

Although osimertinib has achieved remarkable efficacy in the treatment of non-small cell lung cancer, the question of whether it can completely cure lung cancer still needs to be treated with caution. At present, the medical community generally believes that non-small cell lung cancer that can be completely cured is mainly limited to early-stage (Ⅰ-ⅢA stage) patients. Through surgical resection combined with adjuvant therapy such as osimertinib, it is possible to achieve complete tumor removal and cure.

For late stage (ⅢB-For patients with stage IV) non-small cell lung cancer, although osimertinib can significantly prolong survival and improve quality of life, the possibility of complete cure is relatively low. This is mainly because advanced lung cancer has often metastasized far away, and tumor cells may have invaded multiple organs and tissues, making it extremely difficult to completely remove the tumor.

In addition, even if osimertinib shows good efficacy in the initial treatment phase, some patients may develop drug resistance as the treatment time prolongs. This is usually due to a secondary mutation in the tumor cells that renders osimertinib no longer effective in inhibiting their proliferation. Once drug resistance occurs, the patient's condition may progress rapidly and the treatment plan needs to be adjusted in a timely manner.

Osimertinib is mainly targeted at patients with EGFR sensitive mutations. Therefore, genetic testing should be performed before treatment to ensure that patients meet the treatment conditions. According to the patient's specific condition, physical condition, tolerance and other factors, an individualized treatment plan is formulated to ensure that the patient can obtain the best treatment effect.

During the treatment process, patients should be subject to regular clinical assessment and imaging examinations to promptly detect and deal with possible adverse reactions and drug resistance.

For patients with advanced non-small cell lung cancer, osimertinib can be used as a first-line treatment, but it also needs to be considered in combination with other treatments such as chemotherapy and radiotherapy to improve the overall treatment effect.